Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michiel Coppens

Showing results (61-70 of 143) with videos related to

Pageof 15
Sort By:
Thrombosis and Haemostasis|February 8, 2019
Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTEStefano Barco, Serena Granziera, Michiel Coppens, et al.
Thrombosis and Haemostasis|July 10, 2008
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levelsNienke Folkeringa, Michiel Coppens, Nic J G M Veeger, et al.
Blood|August 19, 2021
Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysisAnne-Fleur Zwagemaker, Samantha C Gouw, Julie S Jansen, et al.
Journal of Emergencies, Trauma, and Shock|November 26, 2015
Effects of a hospital-wide introduction of a massive transfusion protocol on blood product ratio and blood product wasteKirsten Balvers, Michiel Coppens, Susan van Dieren, et al.
Thrombosis and Haemostasis|November 15, 2007
Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort studyIvan Bank, Marlène H W van de Poel, Michiel Coppens, et al.
Research and Practice in Thrombosis and Haemostasis|October 27, 2025
Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparinThijs F van Haaps, Alexander P Benz, Lizhen Xu, et al.
Blood|December 17, 2017
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia BWolfgang Miesbach, Karina Meijer, Michiel Coppens, et al.
Research and Practice in Thrombosis and Haemostasis|March 17, 2025
Intrinsic pathway activation in patients with antiphospholipid syndrome and healthy controlsDagmar J M van Mourik, Valérie L B I Jansen, Michiel Coppens, et al.
Blood|January 14, 2009
Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relativesWillem M Lijfering, Jan-Leendert P Brouwer, Nic J G M Veeger, et al.
The Lancet. Haematology|March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trialMichiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.
Pageof 15

Showing results (61-70 of 143) with videos related to

Sort By:
Pageof 15
Thrombosis and Haemostasis|February 8, 2019
Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTEStefano Barco, Serena Granziera, Michiel Coppens, et al.
Thrombosis and Haemostasis|July 10, 2008
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levelsNienke Folkeringa, Michiel Coppens, Nic J G M Veeger, et al.
Blood|August 19, 2021
Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysisAnne-Fleur Zwagemaker, Samantha C Gouw, Julie S Jansen, et al.
Journal of Emergencies, Trauma, and Shock|November 26, 2015
Effects of a hospital-wide introduction of a massive transfusion protocol on blood product ratio and blood product wasteKirsten Balvers, Michiel Coppens, Susan van Dieren, et al.
Thrombosis and Haemostasis|November 15, 2007
Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort studyIvan Bank, Marlène H W van de Poel, Michiel Coppens, et al.
Research and Practice in Thrombosis and Haemostasis|October 27, 2025
Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparinThijs F van Haaps, Alexander P Benz, Lizhen Xu, et al.
Blood|December 17, 2017
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia BWolfgang Miesbach, Karina Meijer, Michiel Coppens, et al.
Research and Practice in Thrombosis and Haemostasis|March 17, 2025
Intrinsic pathway activation in patients with antiphospholipid syndrome and healthy controlsDagmar J M van Mourik, Valérie L B I Jansen, Michiel Coppens, et al.
Blood|January 14, 2009
Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relativesWillem M Lijfering, Jan-Leendert P Brouwer, Nic J G M Veeger, et al.
The Lancet. Haematology|March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trialMichiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.
Pageof 15